CRISPR Therapeutics (NASDAQ: CRSP) has reached a very important chapter in its growth story. The gene-editing specialist doesn't have products on the market right now, but that could change in just a few weeks. The U.S. Food and Drug Administration (FDA) is set to decide on exa-cel, the company's gene-editing candidate for sickle cell disease, next month.

An approval could be the first step toward blockbuster status for the candidate. I say "first step" because regulators will decide on exa-cel as a treatment for a second blood disorder -- beta thalassemia -- in March. And CRISPR Therapeutics and partner Vertex Pharmaceuticals also are working on trials to expand use of the potential therapy to younger patients. Does all of this mean now is the time to buy CRISPR Therapeutics? Let's find out.

Image source: Getty Images.

Continue reading

Source Fool.com